Navegar por autor "López Fernández, María Fernanda"

A novel mutation in ADAMTS13 of a child with Upshaw-Schulman Syndrome

2014- López Fernández, María Fernanda; Batlle Fonrodona, Francisco Javier; Perez Rodriguez, Almudena; Lourés Fraga, Esther; Rodríguez Trillo, Angela; [et al.]

Acquired von Willebrand syndrome (AVWS) in patients with cardiovascular disorders: a single centre cohort study

2015- López Fernández, María Fernanda; Batlle Fonrodona, Francisco Javier; Costa Pinto Prego de Faria, María Joana; Perez Rodriguez, Almudena; Gomez Del Castillo, Mª Del Carmen [et al.]

Acquired von Willebrand syndrome and mitral valve prosthesis leakage. A pilot study

2011- Cuenca Castillo, Jose Joaquin; López Fernández, María Fernanda; Batlle Fonrodona, Francisco Javier; Costa Pinto Prego de Faria, María Joana; Perez Rodriguez, Almudena; [et al.]

Adherence to prophylaxis and quality of life in children and adolescents with severe haemophilia A

2015- López Fernández, María Fernanda

Adverse events in treatment of inherited factor VII deficiency: Final analysis of the ster

2012- López Fernández, María Fernanda

BAY 81-8973 demonstrated efficacy, safety and joint status improvement in patients with severe haemophilia A in the LEOPOLD I extension for ?2 years

2020- Mahlangu, Johnny; López Fernández, María Fernanda; Santagostino, Elena; Lalezari, Shadan; Tseneklidou-Stoeter, Despina; [et al.]

Case-Control Pilot Study of the Immune Modulating Effect of FEIBA (R) on Patients with Haemophilia a and Inhibitors

2015- López Fernández, María Fernanda

Choice of treatment and target parameters in von Willebrand disease (VWD) patients undergoing surgery: a survey of current practice in Europe

2014- López Fernández, María Fernanda

Continuous infusion in haemophilia: Current practice in Europe

2012- López Fernández, María Fernanda

Cost of immune tolerance induction in hemophilia a patients: Results from the ITER study

2011- López Fernández, María Fernanda

Coste por paciente con respuesta a romiplostim y rituximab en el tratamiento de la trombocitopenia inmune primaria en España

2015- López Fernández, María Fernanda

Deciphering predictive factors for choice of thrombopoietin receptor agonist, treatment free responses, and thrombotic events in immune thrombocytopenia

2019- Lozano, Maria L; Mingot-Castellano, Maria E; Perera, Maria M; Jarque, Isidro; Campos-Alvarez, Rosa M; [et al.]

Identification of mutations in the protein C gene in a panel of 65 Spanish families with protein C deficiency

2012- López Fernández, María Fernanda; Costa Pinto Prego de Faria, María Joana

Inherited ADAMTS13 deficiency (Upshaw-Schulman syndrome): a short review

2014- López Fernández, María Fernanda; Batlle Fonrodona, Francisco Javier; Costa Pinto Prego de Faria, María Joana; Perez Rodriguez, Almudena; Lourés Fraga, Esther; [et al.]

Initial results of a clinical trial evaluating a full-length pegylated recombinant factor viii with extended half-life for the perioperative control of hemostasis in hemophilia A

2015- López Fernández, María Fernanda

IPI AND INFECTION BY EPSTEIN BARR VIRUS AS PROGNOSTIC FACTORS IN SLPT

2015- López Fernández, María Fernanda; Pombo Otero, Jorge; Alvarez García, Augusto; Torres Carrete, Juan Pío; Torrado Chedas, Tamara; [et al.]

Management of Adult Patients with Primary Immune Thrombocytopenia (ITP) in Clinical Practice: A Consensus Approach of the Spanish ITP Expert Group

2019- Mingot-Castellano, M Eva; Roman, M Teresa Alvarez; Fernandez Fuertes, Luis Fernando; Gonzalez-Lopez, Tomas Jose; Guinea de Castro, Jose Maria; [et al.]

Repositorio digital RUNA

Navegar por autor "López Fernández, María Fernanda"

A novel mutation in ADAMTS13 of a child with Upshaw-Schulman Syndrome ﻿

Acquired von Willebrand syndrome (AVWS) in patients with cardiovascular disorders: a single centre cohort study ﻿

Acquired von Willebrand syndrome and mitral valve prosthesis leakage. A pilot study ﻿

Adherence to prophylaxis and quality of life in children and adolescents with severe haemophilia A ﻿

Adverse events in treatment of inherited factor VII deficiency: Final analysis of the ster ﻿

BAY 81-8973 demonstrated efficacy, safety and joint status improvement in patients with severe haemophilia A in the LEOPOLD I extension for ?2 years ﻿

Case-Control Pilot Study of the Immune Modulating Effect of FEIBA (R) on Patients with Haemophilia a and Inhibitors ﻿

Choice of treatment and target parameters in von Willebrand disease (VWD) patients undergoing surgery: a survey of current practice in Europe ﻿

Continuous infusion in haemophilia: Current practice in Europe ﻿

Cost of immune tolerance induction in hemophilia a patients: Results from the ITER study ﻿

Coste por paciente con respuesta a romiplostim y rituximab en el tratamiento de la trombocitopenia inmune primaria en España ﻿

Deciphering predictive factors for choice of thrombopoietin receptor agonist, treatment free responses, and thrombotic events in immune thrombocytopenia ﻿

Diagnosis and management of von Willebrand disease in Spain ﻿

Diagnóstico, tratamiento y seguimiento de la trombocitopenia inmune primaria ﻿

GRANULOCYTAPHERESIS IN ULCERATIVE COLITIS. EXPERIENCE IN A CENTRE ﻿

Identification of mutations in the protein C gene in a panel of 65 Spanish families with protein C deficiency ﻿

Inherited ADAMTS13 deficiency (Upshaw-Schulman syndrome): a short review ﻿

Initial results of a clinical trial evaluating a full-length pegylated recombinant factor viii with extended half-life for the perioperative control of hemostasis in hemophilia A ﻿

IPI AND INFECTION BY EPSTEIN BARR VIRUS AS PROGNOSTIC FACTORS IN SLPT ﻿

Management of Adult Patients with Primary Immune Thrombocytopenia (ITP) in Clinical Practice: A Consensus Approach of the Spanish ITP Expert Group ﻿

A novel mutation in ADAMTS13 of a child with Upshaw-Schulman Syndrome

Acquired von Willebrand syndrome (AVWS) in patients with cardiovascular disorders: a single centre cohort study

Acquired von Willebrand syndrome and mitral valve prosthesis leakage. A pilot study

Adherence to prophylaxis and quality of life in children and adolescents with severe haemophilia A

Adverse events in treatment of inherited factor VII deficiency: Final analysis of the ster

BAY 81-8973 demonstrated efficacy, safety and joint status improvement in patients with severe haemophilia A in the LEOPOLD I extension for ?2 years

Case-Control Pilot Study of the Immune Modulating Effect of FEIBA (R) on Patients with Haemophilia a and Inhibitors

Choice of treatment and target parameters in von Willebrand disease (VWD) patients undergoing surgery: a survey of current practice in Europe

Continuous infusion in haemophilia: Current practice in Europe

Cost of immune tolerance induction in hemophilia a patients: Results from the ITER study

Coste por paciente con respuesta a romiplostim y rituximab en el tratamiento de la trombocitopenia inmune primaria en España

Deciphering predictive factors for choice of thrombopoietin receptor agonist, treatment free responses, and thrombotic events in immune thrombocytopenia

Diagnosis and management of von Willebrand disease in Spain

Diagnóstico, tratamiento y seguimiento de la trombocitopenia inmune primaria

GRANULOCYTAPHERESIS IN ULCERATIVE COLITIS. EXPERIENCE IN A CENTRE

Identification of mutations in the protein C gene in a panel of 65 Spanish families with protein C deficiency

Inherited ADAMTS13 deficiency (Upshaw-Schulman syndrome): a short review

Initial results of a clinical trial evaluating a full-length pegylated recombinant factor viii with extended half-life for the perioperative control of hemostasis in hemophilia A

IPI AND INFECTION BY EPSTEIN BARR VIRUS AS PROGNOSTIC FACTORS IN SLPT

Management of Adult Patients with Primary Immune Thrombocytopenia (ITP) in Clinical Practice: A Consensus Approach of the Spanish ITP Expert Group